Status In progress
Process STA
ID number 1136

Provisional Schedule

Expected publication 25 April 2018

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb
Others Department of Health
  NHS England
  NHS Knowsley CCG
  NHS St Helens CCG
  Welsh Government
Patient carer groups Beating Bowel Cancer
  Black Health Agency
  Bladder and Bowel Community
  Bowel Cancer Information
  Bowel Cancer UK
  Cancer Black Care
  Cancer Equality
  Colostomy Association
  HAWC
  Helen Rollason Cancer Charity
  IA: lleostomy and Internal Pouch Support Group
  Independent Cancer Patients Voice
  Lynch Syndrome UK
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  British Geriatrics Society
  British Institute for Radiology
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Research UK
  Pelican Cancer Foundation
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (irinotecan, fluorouracil, oxaliplatin)
  Actavis UK (capecitabine, irinotecan, oxaliplatin)
  Almirall (fluorouracil)
  Hospira UK (irinotecan, folinic acid, fluorouracil, oxaliplatin, raltitrexed)
  Meda Pharmaceuticals (fluorouracil)
  Medac (folinic acid, fluorouracil, oxaliplatin)
  Pfizer (irinotecan)
  Roche (capecitabine)
  Seacross pharmaceuticals (irinotecan)
  Servier Laboratories (trifludine-tipiracil)
  Sun Pharmaceutical Industries Ltd (oxaliplatin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bowel & Cancer Research
  Cochrane Colorectal Cancer Group
  CORE (Digestive Disorders Foundation)
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
16 November 2017 Committee meeting: 1
26 June 2017 In progress, Appraisal has started
23 June 2017 Invitation to participate
23 March 2017 - 13 April 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
02 March 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance